3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Interventions
Rituximab
2
Lenalidomide
2
umbralisib
1
ublituximab
1
tisagenlecleucel
1
tazemetostat
1
tafasitamab
1
selinexor
1
prednisolone phosphate
1
prednisolone acetate
1
polatuzumab vedotin
1
Vincristine
1
Prednisone
1
Prednisolone
1
Methylprednisolone
1
Doxorubicin
1
Cyclophosphamide
1
Brentuximab Vedotin
1
Bendamustine Hydrochloride
1
Appointments and Schedules
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Lymphoma, Large B-Cell, Diffuse
×
tafasitamab
×
Clear all
NCT02399085
2023-10-23
L-MIND
MorphoSys AG
Phase 2
Completed
81 enrolled
23 charts
1 FDA